Physician profile
Syed A Asad
NPI 1497851042
$302,251.68
in general payments reported to CMS, 2019-2025
80 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106K · 2020: $17K · 2021: $79K · 2022: $40K · 2023: $40K · 2024: $5,519 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Food and Beverage: $13K · Consulting Fee: $7,866 · Travel and Lodging: $6,123 · Education: $534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,573.50 |
| Food and Beverage | $12,889.67 |
| Consulting Fee | $7,866.00 |
| Travel and Lodging | $6,123.21 |
| Education | $534.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $169,551.78 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $32,443.56 | 2023-2025 | Nuedexta, Rexulti |
| Biohaven Pharmaceuticals, INC. | $24,575.69 | 2021 | |
| Abbvie INC. | $22,384.64 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Jazz Pharmaceuticals INC. | $10,807.53 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $7,708.88 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $5,358.70 | 2022 | |
| Allergan, INC. | $3,229.07 | 2019-2022 | |
| Amgen INC. | $2,568.79 | 2019-2025 | Aimovig, Uplizna |
| Argenx US, INC. | $2,542.38 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $1,685.17 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Emd Serono, INC. | $1,332.21 | 2019-2025 | Mavenclad |
| Abbott Laboratories | $1,259.63 | 2019-2023 | Infinity |
| Supernus Pharmaceuticals, INC. | $1,248.92 | 2019-2022 | |
| Lundbeck LLC | $1,017.89 | 2020-2025 | Vyepti, Rexulti |
Show all 79 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,006.59 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Medtronic, INC. | $944.10 | 2022 | |
| Biogen, INC. | $886.99 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Eisai INC. | $832.18 | 2019-2025 | |
| Pfizer INC. | $743.72 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $738.93 | 2019-2024 | Ultomiris |
| Genentech USA, INC. | $662.90 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Csl Behring | $651.91 | 2019-2025 | Hizentra |
| Ucb, INC. | $499.72 | 2020-2025 | Nayzilam, Briviact, Rystiggo |
| Kyowa Kirin, INC. | $490.11 | 2020-2025 | Nourianz |
| Mdd US Operations, LLC | $453.49 | 2019-2025 | Gocovri |
| Boston Scientific Corporation | $438.56 | 2019-2025 | Vercise, General - Pain Management |
| Genzyme Corporation | $426.76 | 2019-2023 | |
| Acadia Pharmaceuticals INC | $367.96 | 2019-2025 | Nuplazid |
| Adamas Pharmaceuticals, INC. | $366.84 | 2019-2021 | |
| Medtronic USA, INC. | $333.49 | 2019 | |
| Upsher-Smith Laboratories LLC | $319.91 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $264.19 | 2020-2025 | Ongentys, Ingrezza |
| Neuronetics, INC. | $253.99 | 2021-2022 | |
| Neurelis, INC. | $251.61 | 2021-2025 | Valtoco |
| Tg Therapeutics, INC. | $235.23 | 2024-2025 | |
| Axsome Therapeutics, INC. | $222.01 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $188.91 | 2024-2025 | Hyqvia |
| Celgene Corporation | $187.14 | 2021-2025 | Zeposia |
| Vanda Pharmaceuticals INC. | $174.33 | 2024-2025 | Ponvory |
| Corium, LLC | $154.24 | 2022-2023 | Adlarity |
| Livanova USA, INC. | $153.71 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Janssen Pharmaceuticals, INC | $145.66 | 2021-2025 | Spravato |
| Promius Pharma LLC | $130.27 | 2019 | |
| Zyla Life Sciences, INC. | $122.60 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $111.13 | 2020-2022 | |
| Assertio Therapeutics, INC. | $110.20 | 2019 | |
| Mallinckrodt Hospital Products INC. | $102.05 | 2020-2023 | Acthar |
| Greenwich Biosciences, INC. | $101.27 | 2019-2021 | |
| Almatica Pharma LLC | $92.53 | 2021-2023 | Gralise |
| Sk Life Science, INC. | $90.31 | 2022-2024 | |
| Tersera Therapeutics LLC | $88.18 | 2019 | |
| Grifols USA, LLC | $82.61 | 2019-2024 | Gamunex-C |
| Bausch Health US, LLC | $78.86 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $78.34 | 2021-2025 | Xeomin |
| Catalyst Pharmaceuticals, INC. | $77.51 | 2020-2025 | |
| Arbor Pharmaceuticals, INC. | $73.19 | 2019-2022 | |
| Tanabe Pharma America, INC. | $71.30 | 2019-2024 | |
| Janssen Biotech, INC. | $71.15 | 2025 | |
| Acorda Therapeutics, INC | $70.82 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $63.36 | 2019 | |
| Merz North America, INC. | $53.59 | 2019-2020 | |
| Impel Pharmaceuticals LLC | $44.18 | 2025 | Trudhesa |
| Flowonix Medical Incorporated | $43.23 | 2020 | |
| Microtransponder, INC. | $42.10 | 2025 | |
| Currax Pharmaceuticals LLC | $39.36 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $35.33 | 2020 | |
| Globus Medical, INC. | $34.79 | 2025 | Senza |
| Merck Sharp & Dohme LLC | $33.52 | 2022 | |
| C2n Diagnostics, LLC | $28.95 | 2025 | Precivityad2 |
| Amneal Pharmaceuticals LLC | $22.42 | 2024 | Ongentys |
| Averitas Pharma INC. | $21.49 | 2023 | Qutenza |
| Immedica Pharma US, INC. | $20.98 | 2023 | |
| Octapharma USA, INC. | $19.28 | 2024 | Panzyga |
| Inspire Medical Systems, INC. | $19.21 | 2025 | Inspire |
| Azurity Pharmaceuticals, INC. | $18.43 | 2024 | Horizant |
| Aucta Pharmaceuticals, INC. | $17.30 | 2025 | Motpoly Xr |
| Vertical Pharmaceuticals, LLC | $16.52 | 2019 | |
| Insightec,INC | $15.30 | 2025 | Exablate |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Asad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.